Our Innovative Solution

Monoclonal antibodies (mAbs) are one of the most desirable targeting vectors to carry the radiation to tumour cells due to the exquisite specificity. Unfortunately, and in contrast to peptides, mAbs accumulate slowly into cancers and excrete slowly from the rest of the body. This characteristic disqualifies mAbs for almost all RLTs as the initial radiation represents a burden on healthy tissues and limits the dose that can be administered. Our pretargeting platform, which separates the (non-radioactive) mAb accumulation and excretion from the actual radioactivity administration, circumvents this intrinsic radiotoxicity challenge and takes full advantage of their precision.